Briobacept

Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3) and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) [1][2].

Product Specifications

CAS Number

[869881-54-9]

Product Name Alternative

BR 3FC

UNSPSC

12352203

Target

ADC Antibody

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/briobacept.html

Purity

97.66

Solubility

10 mM in DMSO

Smiles

[Briobacept]

Molecular Weight

(65.75 kDa)

References & Citations

[1]Sifuentes Giraldo WA, et al. New targets in systemic lupus (part 2/2) . Reumatol Clin. 2012 Sep-Oct;8 (5) :263-9. |[2]Liu Yunjie, et al. Research progress on the pathogenesis and drug targeting therapy of B lymphocyte stimulator-induced rheumatoid arthritis. 2011;22 (33) :3152-3154. |[3]La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther. 2010 Nov;10 (11) :1555-61. |[4]Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002 Oct;17 (4) :515-24.